Howard WELGUS,Archie W. THURSTON, JR.,David W. Osborne
申请号：
US16563435
公开号：
US20200155524A1
申请日:
2019.09.06
申请国别(地区):
US
年份:
2020
代理人:
摘要：
A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.
